Interpreting the economic literature in oncology

Journal of Clinical Oncology

Volumn 25, Issue 2, 2007, Pages 196-202

  Grusenmeyer, Patrick A ^a   Wong, Yu Ning ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CISPLATIN; DOXORUBICIN; GEMCITABINE; TAMOXIFEN; TOPOTECAN; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ADVANCED CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHEMOPROPHYLAXIS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HORMONAL THERAPY; HUMAN; MONOTHERAPY; OVARY CANCER; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; REVIEW; BREAST TUMOR; ECONOMICS; FEMALE; METHODOLOGY; ONCOLOGY; OVARY TUMOR; PROBABILITY; PUBLICATION; SALVAGE THERAPY; STANDARD; STATISTICAL MODEL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; MEDICAL ONCOLOGY; MODELS, ECONOMIC; OVARIAN NEOPLASMS; PERIODICALS; SALVAGE THERAPY;

EID: 33846978420     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.0738     Document Type: Review

References (40)

1. Smith C, Cowan C, Heffler S, et al: National health spending in 2004: Recent slowdown led by prescription drug spending. Health Aff (Millwood) 25:186-196, 2006
2. Heffler S, Smith S, Keehan S, et al: U.S. health spending projections for 2004-2014. Health Aff (Millwood) Suppl Web Exclusives 24:W5-74-W5-85, 2005 (suppl 1)
3. Heffler S, Smith S, Keehan S, et al: Health spending projections through 2013. Health Aff (Millwood) Suppl Web Exclusives 23:W4-79-93, 2004
4. Borger C, Smith S, Truffer C, et al: Health spending projections through 2015: Changes on the horizon. Health Aff (Millwood) 25:w61-w73, 2006
5. Iglehart JK: Medicare and drug pricing. N Engl J Med 348:1590-1597, 2003
6. Halbert RJ, Zaher C, Wade S, et al: Outpatient cancer drug costs: Changes, drivers, and the future. Cancer 94:1142-1150, 2002
7. Meropol NJ, Schulman KA: The cost of cancer care: Issues and implications. J Clin Oncol 25:180-186, 2007
8. DiMasi JA, Grabowski HG: The economics of new cncology drug development. J Clin Oncol 25: 209-216, 2007
9. Siegel JE, Weinstein MC, Russell LB, et al: Recommendations for reporting cost-effectiveness analyses: Panel on Cost-Effectiveness in Health and Medicine. JAMA 276:1339-1341, 1996
10. Weinstein MC, Siegel JE, Gold MR, et al: Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 276:1253-1258, 1996
11. Russell LB, Gold MR, Siegel JE, et al: The role of cost-effectiveness analysis in health and medicine: Panel on Cost-Effectiveness in Health and Medicine. JAMA 276:1172-1177, 1996
12. Neumann PJ, Greenberg D, Olchanski NV, et al: Growth and quality of the cost-utility literature, 1976-2001. Value Health 8:3-9, 2005
13. Earle CC, Chapman RH, Baker CS, et al: Systematic overview of cost-utility assessments in oncology. J Clin Oncol 18:3302-3317, 2000
14. Drummond MF, Richardson WS, O'Brien BJ, et al: Users' guides to the medical literature: XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 277:1552-1557, 1997
15. O'Brien BJ, Heyland D, Richardson WS, et al: Users' guides to the medical literature: XIII. How to use an article on economic analysis of clinical practice. B. What are the results and will they help me in caring for my patients? Evidence-Based Medicine Working Group. JAMA 277:1802-1806, 1997 [Erratum: JAMA 278:1064, 1997]
16. Melnikow J, Kuenneth C, Helms LJ, et al: Chemoprevention: Drug pricing and mortality - The case of tamoxifen. Cancer 107:950-958, 2006
17. Hillner BE: Benefit and projected costeffectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 101:1311-1322, 2004
18. Rocconi RP, Case AS, Straughn JM Jr, et al: Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis. Cancer 107:536-543, 2006
19. Institute of Medicine, Board on Health Care Services, Committee on the Consequences of Uninsurance: Hidden Costs, Values Lost Uninsurance in America. Washington, DC, National Academies Press, 2003
20. Sanders GD, Hlatky MA, Owens DK: Costeffectiveness of implantable cardioverter-defibrillators. N Engl J Med 353:1471-1480, 2005
21. Sonnenberg FA, Beck JR: Markov models in medical decision making: A practical guide. Med Decis Making 13:322-338, 1993
22. Drummond MF, O'Brian B, Stoddart GL, et al: Methods for the Economic Evaluation of Health Care Programmes (ed 2). Oxford, United Kingdom, Oxford University Press, 1997
23. Tufts-New England Medical Center: The CEA Registry. http://www.tufts- nemc.org/cearegistry/index.html
24. Brown RE, Hutton J, Burrell A: Cost effectiveness of treatment options in advanced breast cancer in the UK. Pharmacoeconomics 19:1091-1102, 2001
25. Gold MR, Siegel JE, Russell LB, et al: Cost-Effectiveness in Health and Medicine. New York, NY, Oxford University Press, 1996
26. Hartmann M, Knoth H, Schulz D, et al: Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations. Br J Cancer 89:1405-1408, 2003
27. Friedberg M, Saffran B, Stinson TJ, et al: Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 282: 1453-1457, 1999
28. Dranitsaris G, Verma S, Trudeau M: Cost utility analysis of first-line hormonal therapy in advanced breast cancer: Comparison of two aromatase inhibitors to tamoxifen. Am J Clin Oncol 26:289-296, 2003
29. Wilson LS, Reyes CM, Lu C, et al: Modelling the cost-effectiveness of sentinel lymph node mapping and adjuvant interferon treatment for stage II melanoma. Melanoma Res 12:607-617, 2002
30. Mahadevia PJ, Fleisher LA, Frick KD, et al: Lung cancer screening with helical computed tomography in older adult smokers: A decision and costeffectiveness analysis. JAMA 289:313-322, 2003
31. Hur C, Nishioka NS, Gazelle GS: Costeffectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia. Dig Dis Sci 48:1273-1283, 2003
32. Blake GJ, Ridker PM, Kuntz KM: Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia. Am J Med 114: 485-494, 2003
33. Ramsey SD, Berry K, Etzioni R, et al: Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med 348:2092-2102, 2003
34. Zhou F, Bisgard KM, Yusuf HR, et al: Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: An economic analysis. Pediatrics 110:653-661, 2002
35. Garber A: Cost effectiveness and evidence evaluation as criteria for coverage policy. Health Aff W4-284-W4-292, 2004
36. Neumann PJ: Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers. New York, NY, Oxford University Press, 2005
37. Pearson SD, Rawlins MD: Quality, innovation, and value for money: NICE and the British National Health Service. JAMA 294:2618-2622, 2005
38. Neumann PJ, Rosen AB, Weinstein MC: Medicare and cost-effectiveness analysis. N Engl J Med 353:1516-1522, 2005
39. Fuchs VR: Health care expenditures reexamined. Ann Intern Med 143:76-78, 2005
40. Hall RE, Jones CI: The value of life and the rise in healthcare spending. Q J Econ 2007 (in press)